english.prescrire.org > Prescrire International > N°160 - May 2015

n°160

May 2015

Issue Contents
Editorial

Free  Being pragmatic

p.116
Ease of drug use must not be ignored

New Products


Afatinib (Giotrif°)

p.117
Non-small cell lung cancer: just another "tinib"

Blurred vision

p.117

Loxapine (Adasuve°) for inhalation

p.118-119
A dangerous gadget

Lenalidomide (Revlimid°) and myelodysplastic syndromes

p.119
Transfusions are preferable, despite their constraints

Free  Simeprevir (Olysio°)

p.120
Chronic hepatitis C: an option for some patients

Free  INN common stem: -pamide

p.120

Eculizumab (Soliris°) and paroxysmal nocturnal haemoglobinuria in children

p.121
When transfusions are too frequent

Adverse Effects


Human papillomavirus vaccines: 2014 safety review

p.122-129
No signs of disproportionate harms

Efficacy of HPV vaccine in late 2014

p.126-127

Reviews


Glucose-lowering treatment of type 2 diabetes

p.130-135
Part II - Glucose-lowering drugs after metformin: a choice based largely on adverse effects

Type 2 diabetes: which glucose-lowering drug, if any, after metformin?

p.135
Prescrire's advice

Outlook


Free  Drug packaging in 2014

p.136-138
Authorities should direct more efforts towards medication safety

Free  Access to data: EMA in key position

p.139
Resisting industry pressure

Masthead


Free  Masthead

p.114

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe